Compare AegirBio AB with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate 0.41% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -14.00
2
Flat results in Sep 24
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
SEK 121 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.14
127.53%
-3.13
Revenue and Profits:
Net Sales:
47 Million
(Quarterly Results - Mar 2026)
Net Profit:
-15 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
112.12%
0%
112.12%
6 Months
285.83%
0%
285.83%
1 Year
-29.39%
0%
-29.39%
2 Years
-75.45%
0%
-75.45%
3 Years
-97.39%
0%
-97.39%
4 Years
-99.47%
0%
-99.47%
5 Years
0%
0%
0.0%
AegirBio AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-100.00%
EBIT Growth (5y)
0.41%
EBIT to Interest (avg)
-14.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.14
Sales to Capital Employed (avg)
0.01
Tax Ratio
2.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.01
EV to EBIT
-0.80
EV to EBITDA
-0.80
EV to Capital Employed
8.28
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1029.83%
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
204.40
203.80
0.29%
Operating Profit (PBDIT) excl Other Income
-66.70
-24.20
-175.62%
Interest
16.70
9.60
73.96%
Exceptional Items
-1.90
6.80
-127.94%
Consolidate Net Profit
-49.60
26.20
-289.31%
Operating Profit Margin (Excl OI)
-446.50%
-237.30%
-20.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.29% vs 2,03,700.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -289.31% vs 143.89% in Dec 2024
About AegirBio AB 
AegirBio AB
Pharmaceuticals & Biotechnology
Aegirbio AB is a Sweden-based diagnostic company that offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. The company's tests for optimized dosage of biological drugs focused on diseases in neurology, autoimmune diseases and cancer.
Company Coordinates 
Company Details
C/o IDEON SCIENCE PARK, Solvegatan 43 , LUND None : 223 70
Registrar Details






